Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; and Inogen At Home stationary oxygen concentrators, as well as related accessories. The company also rents its products directly to patients. Inogen, Inc. was founded in 2001 and is headquartered in Goleta, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INGN
CUSIPN/A
Phone805-562-0500
Debt
Debt-to-Equity RatioN/A
Current Ratio5.99
Quick Ratio5.41
Price-To-Earnings
Trailing P/E Ratio178.37
Forward P/E Ratio113.43
P/E Growth4.6
Sales & Book Value
Annual Sales$249.44 million
Price / Sales20.00
Cash Flow$1.9674 per share
Price / Cash118.77
Book Value$10.88 per share
Price / Book21.48
Profitability
EPS (Most Recent Fiscal Year)$1.31
Net Income$21 million
Net Margins10.39%
Return on Equity16.51%
Return on Assets13.48%
Miscellaneous
Employees770
Outstanding Shares21,350,000
Market Cap$4.97 billion
Inogen (NASDAQ:INGN) Frequently Asked Questions
What is Inogen's stock symbol?
Inogen trades on the NASDAQ under the ticker symbol "INGN."
How were Inogen's earnings last quarter?
Inogen Inc (NASDAQ:INGN) issued its quarterly earnings data on Tuesday, August, 7th. The medical technology company reported $0.65 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.44 by $0.21. The medical technology company had revenue of $97.24 million for the quarter, compared to analyst estimates of $81.61 million. Inogen had a net margin of 10.39% and a return on equity of 16.51%. View Inogen's Earnings History.
When is Inogen's next earnings date?
What price target have analysts set for INGN?
6 brokers have issued 1-year price targets for Inogen's shares. Their forecasts range from $170.00 to $258.00. On average, they anticipate Inogen's stock price to reach $221.40 in the next twelve months. This suggests that the stock has a possible downside of 5.3%. View Analyst Price Targets for Inogen.
What is the consensus analysts' recommendation for Inogen?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inogen in the last year. There are currently 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Inogen.
What are Wall Street analysts saying about Inogen stock?
Here are some recent quotes from research analysts about Inogen stock:
- 1. According to Zacks Investment Research, "Inogen outperformed its industry in a year’s time. A solid second quarter and business-to-business and direct-to-consumer sales in the United States are major positives. Management is upbeat about strong contributions from the company’s core direct-to-consumer unit. Strong growth of the company’s business-to-business sales in Europe also buoys optimism. In fact, management expects to see strength in Europe in the quarters ahead. Management is also optimistic about the company’s increasing hiring in Cleveland. Expansion in margins and a raised 2018 guidance are encouraging as well. On the flip side, Inogen’s rental revenues were soft in the quarter. In fact, management expects rental revenues to remain low throughout 2018. Rising operating expenses are discouraging as well. This is likely to keep margins under pressure. Stiff competition in the MedTech space is likely to mar prospects." (8/21/2018)
- 2. Needham & Company LLC analysts commented, "We hosted for management meetings in Boston and Toronto last week. Recent sales and marketing investments (CRM, training, and new hires) are paying off with higher growth. We think INGN’s DTC channel is a competitive advantage and one that is difficult for competitors to copy. INGN is increasingly spending its R&D dollars on research as opposed to development; we expect it to launch the G5 next year. The US POC market remains significantly underpenetrated and international markets, particularly emerging markets, have minimal penetration. Despite facing some much larger competitors, we believe INGN has the best POCs and that it can maintain its lead. We expect INGN to sustain very strong revenue growth for the next few years and to continue to deliver upside to consensus estimates and we reiterate our Strong Buy rating." (6/13/2018)
Who are some of Inogen's key competitors?
Some companies that are related to Inogen include Smith & Nephew (SNN), WILLIAM DEMANT/ADR (WILYY), Steris (STE), MSA Safety (MSA), Avanos Medical (AVNS), Wright Medical Group (WMGI), Halyard Health (HYH), CONSORT Med PLC/S (CSRMY), Sientra (SIEN), Establishment Labs (ESTA), Invacare (IVC), RTI Surgical (RTIX), Lakeland Industries (LAKE), Histogenics (HSGX) and ConforMIS (CFMS).
Who are Inogen's key executives?
Inogen's management team includes the folowing people:
- Mr. Scott Wilkinson, CEO, Pres & Director (Age 53)
- Mr. Brenton Taylor, Exec. VP of Engineering (Age 37)
- Ms. Alison Perry Bauerlein, Exec. VP of Fin., CFO, Corp. Sec. & Treasurer (Age 37)
- Mr. Matthew S. Scribner, Exec. VP of Operations (Age 51)
- Mr. Byron Myers, Exec. VP of Sales & Marketing (Age 39)
Has Inogen been receiving favorable news coverage?
Headlines about INGN stock have trended positive recently, Accern Sentiment reports. The research firm rates the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Inogen earned a media and rumor sentiment score of 0.41 on Accern's scale. They also gave press coverage about the medical technology company an impact score of 47.78 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Inogen.
Who are Inogen's major shareholders?
Inogen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.21%), Dimensional Fund Advisors LP (2.07%), Fred Alger Management Inc. (1.47%), Renaissance Technologies LLC (1.45%), OppenheimerFunds Inc. (1.34%) and Waddell & Reed Financial Inc. (1.02%). Company insiders that own Inogen stock include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Institutional Ownership Trends for Inogen.
Which institutional investors are selling Inogen stock?
INGN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Millennium Management LLC, Rockefeller Capital Management L.P., Wells Fargo & Company MN, Waddell & Reed Financial Inc., Dimensional Fund Advisors LP, Osterweis Capital Management Inc. and Cabot Wealth Management Inc.. Company insiders that have sold Inogen company stock in the last year include Alison Bauerlein, Brenton Taylor, Byron Myers, Heath Lukatch, Heather D Rider, Loren L Mcfarland, Matt Scribner, Ray Benjamin M Anderson, Raymond Huggenberger and Scott Wilkinson. View Insider Buying and Selling for Inogen.
Which institutional investors are buying Inogen stock?
INGN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., OppenheimerFunds Inc., Jennison Associates LLC, Fred Alger Management Inc., Acadian Asset Management LLC, WINTON GROUP Ltd, Renaissance Technologies LLC and State of Wisconsin Investment Board. View Insider Buying and Selling for Inogen.
How do I buy shares of Inogen?
Shares of INGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Inogen's stock price today?
One share of INGN stock can currently be purchased for approximately $233.67.
How big of a company is Inogen?
Inogen has a market capitalization of $4.97 billion and generates $249.44 million in revenue each year. The medical technology company earns $21 million in net income (profit) each year or $1.31 on an earnings per share basis. Inogen employs 770 workers across the globe.
How can I contact Inogen?
Inogen's mailing address is 326 BOLLAY DRIVE, GOLETA CA, 93117. The medical technology company can be reached via phone at 805-562-0500 or via email at [email protected]
MarketBeat Community Rating for Inogen (NASDAQ INGN)
MarketBeat's community ratings are surveys of what our community members think about Inogen and other stocks. Vote "Outperform" if you believe INGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
